1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,748 | 0,810 | 29.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Tevogen Bio Inc: Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure | 69 | GlobeNewswire (Europe) | WARREN, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today updated investors of its significant internally developed assets, which under... ► Artikel lesen | |
| Di | Tevogen Bio Inc: Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health Equity | 1 | GlobeNewswire (USA) | ||
| Mo | Tevogen Bio Inc: Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions | 172 | GlobeNewswire (Europe) | WARREN, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today announced an update on institutional ownership of the Company's outstanding... ► Artikel lesen | |
| 22.08. | Tevogen Bio Inc: Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma | 1 | GlobeNewswire (USA) | ||
| 19.08. | Tevogen Bio Holdings reports Q2 results | 1 | Seeking Alpha | ||
| 19.08. | Tevogen Bio Inc: Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum | 144 | GlobeNewswire (Europe) | Expenses significantly lower with expansion on multiple efforts; Q2 2025 loss from operations reduced to $5.4 million vs $8.6 million in Q2 2024.Tevogen maximizes capital efficiency, maintains access... ► Artikel lesen | |
| 18.08. | Tevogen Bio Inc: Tevogen CEO Donates Personal Shares to Support Local Law Enforcement | 1 | GlobeNewswire (USA) | ||
| TEVOGEN BIO Aktie jetzt für 0€ handeln | |||||
| 18.08. | Tevogen Bio Inc: Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery | 3 | GlobeNewswire (USA) | ||
| 14.08. | Tevogen Bio Holdings Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.08. | Tevogen Bio Inc: Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected | 1 | GlobeNewswire (USA) | ||
| 13.08. | Tevogen Bio Inc: Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell Model With a Focus on Oncology | 5 | GlobeNewswire (USA) | ||
| 11.08. | Tevogen Bio Inc: Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion | 72 | GlobeNewswire (Europe) | WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or the "Company) (Nasdaq: TVGN), reiterates investor confidence and estimated asset value over $10 billion. In... ► Artikel lesen | |
| 11.08. | Tevogen Bio Inc: Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow | 234 | GlobeNewswire (Europe) | Total eligible patients in the US exceed 2 million.Treatment of SARS-CoV-2 infection in solid and hematologic cancer patients under active treatment.Reflects business philosophy of commercial success... ► Artikel lesen | |
| 07.08. | Tevogen Bio Inc: Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy | 2 | GlobeNewswire (USA) | ||
| 06.08. | Tevogen: Institutioneller Anteilsbesitz steigt um 60 % im ersten Quartal 2025 | 3 | Investing.com Deutsch | ||
| 06.08. | Tevogen reports 60% rise in institutional ownership in Q1 2025 | 1 | Investing.com | ||
| 05.08. | Tevogen.AI expands AI collaboration with Microsoft, Databricks for oncology | 5 | Investing.com | ||
| 05.08. | Tevogen Bio Inc: Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell Model With a Focus on Oncology | 118 | GlobeNewswire (Europe) | Tevogen.AI to explore external market opportunities as a potential revenue source. Beta version to incorporate oncology targets, enhancing the accuracy and diversity of the PredicTcell model and potentially... ► Artikel lesen | |
| 01.08. | Tevogen Bio Inc: Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders | 150 | GlobeNewswire (Europe) | WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today released a letter to stockholders. Dear Fellow Stockholders, Tevogen... ► Artikel lesen | |
| 01.08. | Fördermittel für KI-Plattform: Aktie von Tevogen Bio legt zu | - | Investing.com Deutsch |
1 2 3 4 5 Weiter >>
106 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,710 | +0,16 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten Staaten an | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Anleiheemission
QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten... ► Artikel lesen | |
| AMGEN | 245,20 | -0,33 % | Amgen: US-Arzneimittelbehörde weitet Einsatz von Repatha aus | Der US-Biotechkonzern Amgen hat bekannt gegeben, dass die Arzneimittelbehörde FDA den Anwendungsbereich des Cholesterinsenkers Repatha (Wirkstoff: Evolocumab) erweitert hat. Künftig darf das Medikament... ► Artikel lesen | |
| NOVAVAX | 6,377 | -0,20 % | H.C. Wainwright startet Coverage für Novavax mit "Buy"-Rating und Kursziel von 10 US-Dollar | ||
| PALATIN TECHNOLOGIES | - | - | Boehringer Ingelheim Limited: Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases | · Collaboration strengthens Boehringer's pipeline in Eye Health.· Many patients with diabetic retinopathy (DR) continue to experience vision loss or treatment fatigue, underscoring an... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 494,00 | -0,48 % | Regeneron Pharmaceuticals, Inc.: Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis | Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,980 | -1,98 % | INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug | ||
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp.: Sirona Biochem Update to Shareholders on Financial Status and Operations | VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") wishes to provide shareholders with a critical update on the company's financial... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,460 | -2,38 % | COSCIENS Biopharma Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| BIOMARIN PHARMACEUTICAL | 49,940 | +0,24 % | Sanofi snags BioMarin leader to take on CMO role 8 months after Berger's exit | ||
| NUREXONE BIOLOGIC | 0,524 | +3,15 % | NurExone Biologic: Anflug auf ein neues Allzeithoch?! | ||
| ARROWHEAD PHARMACEUTICALS | 18,830 | 0,00 % | Arrowhead (ARWR) Climbs 24.9% on $100-Million Licensing Revenue | ||
| XOMA ROYALTY | 27,800 | 0,00 % | Mural Oncology plc: Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share | WALTHAM, Mass., DUBLIN, Ireland and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company ("Mural"), and XOMA Royalty Corporation... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| PHIO PHARMACEUTICALS | 2,000 | +1,01 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update | Clinical trial advances for INSTASYL siRNA lead product candidate PH-7625th cohort enrolling patients in on-going clinical studyKing of Prussia, Pennsylvania--(Newsfile Corp. - August 14, 2025) - Phio... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report |
TEVOGEN BIO HOLDINGS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,774 Euro und damit -0,77 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TEVOGEN BIO HOLDINGS INC finden Sie auf Wallstreet Online.